RE:RE:RE:RE:Echelon Starts Coverage!!!where is palladium these days? he/she was sooooo big on sernova a year ago. What happened palladium? i sure hope you don't make your money as investment guru. sernova is very badly managed and completely out of control. they have promised all kinds of results and have failed on all fronts. dr toleikis has to be replaced!! oh, and for the record, he is not a medical doctor!!
wwmeinc wrote: I re-posted that article to highlight what Smitty has been saying Elgin1....we were at ~0.26cts in Dec/16 with this article and all kinds of great things were supposed to happen to move the shareprice forward...the 'great news' out of the HemaCure people has fallen on deaf ears in my opinion. As the consortium plans on using the CellPouch for their human cell work... SVA needs to 'mount-up' and ride that product to human trials,ASAP!
When mgmt delivers then they should be applauded....pretty cut and dry in my books. I have got a question: Do you think mgmt and Co.(Who knows how many consultants are on the books today) will be given options(maybe below today's mkt price) when they finally announce an FDA IND trial?
What about the expected Senior US listing?
I question why SVA just did not wait to announce something earth moving before engaging the new expensive IR firm,in my opinion? Considering how much shareholder value has been lost here in the last 10 months or so...the bar is set pretty low in my opinion for them to regain what has been lost.
*****What is the name of the pharma Co. SVA mentions they are going to be expanding their relationship with? Who has access to this information as I believe it should be public....Do the consultants know the name? Does the new IR firm know the name? If anybody would like to provide an update then they should post the information on the company website for all to read or on here for the general public to read as well...and maybe a shareholder or two as well. GLTA
"
With important anticipated catalysts such as near-term initiation of a U.S. clinical trial of its Cell Pouch technologies, expanding pharma collaborations and subsequent expected upgrade of its U.S. listing to a senior exchange, FronTier will assist the company by increasing market awareness through financial market communications, including facilitating in-person introductions for the company with institutional and retail brokers in Canada and throughout the United States, and through media distribution on national television, radio and multiple on-line channels. FronTier has offices in Toronto, Montreal and Calgary. Under the terms of the engagement, FronTier has been retained for a 12-month period at $80,000 per annum plus direct expenses."